In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses targeted therapies, what they are, and how they have changed our approach to treating not just lung cancer, but cancers in general.

Guest: Dr. Vivek Subbiah

Dr. Subbiah is the Chief of Early Phase Drug Development for Sarah Cannon Research Institute. He was previously the Executive Director of Medical Oncology Research for the MD Anderson Cancer Network, where he played a pivotal role in the development and ultimate approval for several agents that we consider essential in the lung cancer world.